Durable multitransgene expression in vivo using systemic, nonviral DNA delivery.

Area of Science:

• Gene therapy
• Biotechnology
• Molecular medicine

Background:

• Recombinant adeno-associated virus (AAV) vectors are promising for monogenic diseases.
• AAV therapies are limited by immune responses and small DNA insert capacity.
• Need for advanced gene delivery platforms to overcome AAV limitations.

Purpose of the Study:

• To evaluate HEDGES, a nonviral gene delivery platform, as an alternative to AAV vectors.
• To assess HEDGES's efficacy in producing therapeutic proteins in immunocompetent mice.
• To determine HEDGES's potential for treating monogenic and polygenic diseases.

Main Methods:

• Utilized HEDGES (high-level extended duration gene expression system), a DNA- and liposome-based nonviral platform.
• Administered HEDGES systemically in immunocompetent mice.
• Measured durable therapeutic protein production, duration of expression, immune response, and toxicity.

Main Results:

• Single systemic HEDGES injection achieved durable therapeutic protein levels without genomic integration.
• HEDGES controlled protein expression duration from weeks to over 1.5 years.
• The platform showed no anti-vector immune response, allowed re-expression, and had minimal transient toxicity.
• HEDGES accommodated larger DNA inserts than AAV, enabling combinatorial gene therapy for polygenic diseases.

Conclusions:

• HEDGES is a potent nonviral gene delivery platform overcoming AAV limitations.
• This system offers durable, controllable, and repeatable gene expression with reduced immunogenicity.
• HEDGES holds significant potential for treating rare monogenic and common polygenic diseases.